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We have previously demonstrated disease-dependent gene delivery in the brain using an
AAV vector responding to NFκB activation as a probe for inflammatory responses. This
vector, injected focally in the parenchyma prior to a systemic kainic acid (KA) injection
mediated inducible transgene expression in the hippocampus but not in the cerebellum,
regions, respectively, known to be affected or not by the pathology. However, such a focal
approach relies on previous knowledge of the model parameters and does not allow to
predict the whole brain response to the disease. Global brain gene delivery would allow to
predict the regional distribution of the pathology as well as to deliver therapeutic factors in
all affected brain regions.We show that self-complementary AAV2/9 (scAAV2/9) delivery in
the adult rat cisterna magna allows a widespread but not homogenous transduction of the
brain. Indeed, superficial regions, i.e., cortex, hippocampus, and cerebellum were more
efficiently transduced than deeper regions, such as striatum, and substantia nigra. These
data suggest that viral particles penetration from the cerebrospinal fluid (CSF) into the
brain is a limiting factor. Interestingly, AAV2/9-2YF a rationally designed capsid mutant
(affecting surface tyrosines) increased gene transfer efficiency approximately fivefold.
Neurons, astrocytes, and oligodendrocytes, but not microglia, were transduced in varying
proportions depending on the brain region and the type of capsid. Finally, after a single
intracisternal injection of scAAV2/9-2YF using the NFκB-inducible promoter, KA treatment
induced transgene expression in the hippocampus and cortex but not in the cerebellum,
corresponding to the expression of the CD11b marker of microglial activation. These data
support the use of disease-inducible vectors administered in the cisterna magna as a tool
to characterize the brain pathology in systemic drug-induced or transgenic disease models.
However, further improvements are required to enhance viral particles penetration into the
brain.
Keywords: AAV, neuroinflammation, inducible vector, cisterna magna, cerebrospinal fluid
INTRODUCTION
Increasing evidence suggests that global brain neuroinflammation
is a key factor in the progression of neurodegenerative diseases
(Dexter and Jenner, 2013). However, a controlled inflammatory
response can also be beneficial for brain repair (London et al.,
2013). Therefore, approaches aiming at the reduction of neuroin-
flammation should use conditional expression of the interfering
factor in excessive stress conditions (Brown and Neher, 2014).
A reduction of toxic intracerebral conditions such as neuroin-
flammation could possibly be achieved through global brain
gene delivery while avoiding the risk of surgery-related local
inflammatory reactions.
Intraperitoneal injection of kainic acid (KA), a model of
temporal lobe epilepsy (Williams et al., 2009), is known to induce
a locoregional inflammatory response in the hippocampus and in
the cortex (Somera-Molina et al., 2009) but not in the cerebellum
(Rong and Baudry, 1996).
In order to specifically express disease-interfering genes it is
desirable to use a disease-regulated vector providing a similar
pattern of transgene expression.
Gene delivery to the whole brain can be achieved through
intravenous administration followed by trans-blood–brain bar-
rier (BBB) passage (Duque et al., 2009; Foust et al., 2009; Mccarty
et al., 2009; Fu et al., 2011; Gray et al., 2011) or by intra-cerebro-
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spinal fluid (CSF) administration followed by passage through the
CSF-brain barrier (Fu et al., 2003, 2010; Samaranch et al., 2012,
2013; Gray et al., 2013). The BBB and CSF-brain barriers being of
different nature, the regions and cell types transduced aswell as the
immune reaction toward the viral capsids and transgene products
are expected to be different. Indeed, intracisternal injections are
characterized by a reduced immune response and maintenance of
transgene expression despite pre-existing immunity as compared
to intravenous injections. However, Samaranch and collabora-
tors (Samaranch et al., 2012) showed that, at least in monkeys,
pre-existing anti-AAV antibodies abrogated brain transduction
following delivery into the cisterna magna CSF. Another advan-
tage of intracisternal versus intravenous injections is the lower
biodistribution in peripheral organs (Gray et al., 2013).
Intracisternal injections of self-complementary (sc) AAV2 in
juvenile mice combined with systemic mannitol administration
(Fu et al., 2003, 2010), of scAAV2/9 and scAAV2/7 in non-human
primates (Mccarty et al., 2009; Gray et al., 2011, 2013; Samaranch
et al., 2013) as well as of scAAV2/9 and scAAV2/1 in the cat (Bucher
et al., 2013) have been described with reports of neurons and
astrocytes being transduced in the brain and spinal cord.
Largely documented models hypothesize that the CSF pro-
duced in the choroid plexus of the lateral ventricles, travels
to the cisterna magna, then to the subarachnoid space and
further moves into the brain in the perivascular Virchow-
Robin space surrounding penetrating cerebral arteries. Con-
sistently with this model, large molecules tracers (2000 kD)
injected in the cisterna magna accumulate along perivascu-
lar spaces mainly in superficial layers (cortex; Iliff et al.,
2012). As predicted by these models, AAV-mediated gene
delivery after intracisternal injection was maximal in regions
close to Virchow-Robin subarachnoid space (cerebellum and
cortex) and reduced in deeper regions (Samaranch et al.,
2013).
It has recently been shown that gene delivery to the retina and
the brain of neonatal mice through systemic intravenous injection
of AAV2/9 was enhanced by a capsid mutant in which two tyro-
sine residues presumably involved in capsid ubiquitination were
replaced by phenylalanines (Dalkara et al., 2012). Here we investi-
gated whether such mutations could also enhance gene delivery to
the brain after intra-CSF delivery.
We compared the distribution and cell-type specificity of
gene transfer into the brain after intracisternal injection of
scAAV2/9 and the 2YF capsid mutant in the adult rat brain.
With both vectors, gene transfer was prominent in the cere-
bellum and in the cortex with neurons, astrocytes and oligo-
dendrocytes, but not microglia, being targeted in differ-
ent proportions. The 2YF capsid mutant affected both the
global efficiency and the proportions of neurons and glial
cells.
We showed that, as expected, intraperitoneal KA injection
induced transgene expression from a cisternally injected NFκB-
inducible scAAV2/9-2YF vector in the cortex and hippocampus
but not in the cerebellum.
Pathology-inducible gene transfer could be used to probe
pathological events as well as for regulated therapeutic gene
delivery specifically in diseased brain regions.
MATERIALS AND METHODS
PLASMIDS
The pSC-NF8-d1-EGFP plasmid containing eight NFκB
responsive elements (two blocks of four consensus sequences, sep-
arated by 16 bps) fused to a minimal CMV promoter has been
previously described (Chtarto et al., 2013).
ThepHpaI-EGFP self-complementaryAAV(scAAV) vectorwas
a kind gift from D. McCarty and R. J. Samulski (Mccarty et al.,
2003).
The pAAV2/9 and pAd Delta F6 were a kind gift from the
Pen Vector Core (University of Pennsylvania). pAAV2/9-2YF was
previously described (Dalkara et al., 2012).
VIRAL PRODUCTION
To produce recombinant scAAV2/9-CMV-EGFP, scAAV2/9-2YF-
CMV-EGFP and scAAV2/9-NF8-d1-EGFP viral stocks,HEK-293T
cells (5.0 × 106 cells seeded on 10 cm plates) were co-transfected
using polyethylenimine (PEI) from Polysciences, using a 5:1 (v:w)
PEI:DNA ratio and a 2:3:5molar ratio of vector plasmid, pAd plas-
mid and pAAV2/9 or pAAV2/9 2YF packaging plasmid expressing
the AAV viral genes (rep gene from AAV serotype 2 and cap gene
from AAV serotype 9 or from the 2YF tyrosine mutant). Fifty
hours post-transfection, the medium was discarded and the cells
were harvested by low-speed centrifugation and resuspended in
Tris pH 8.0, NaCl 0.1 M. After 5 cycles of freezing/thawing, the
lysate was clarified by 30 min centrifugation at 10 000 g, treated
with benzonase (50 μ/ml) at 37◦C for 30 min, and centrifuged at
10 000 g for 30 min to eliminate the residual debris. The virus
was further purified by iodixanol gradient. Viral genomes (vg)
were titrated by quantitative PCR using primers located in the
SV40polyA sequence (forward primer: AGC AAT AGC ATC ACA
AAT TTC ACA A; reverse primer: CCA GAC ATG ATA AGA TAC
ATT GAT GAG TT; internal probe: 6FAM- AGC ATT TTT TTC
ACT GCA TTC TAG TTG TGG TTT GTC-TAMRA). The PCR
reaction included a pre-denaturing step of 10min at 95◦C followed
by 40 cycles of the 2 following steps: 95◦C for 15 s and 60◦C for
1 min. (Lock et al., 2010). Titers were 1,4 × 1013 vg/ml, 2.0 × 1013
vg/ml and 5,8× 1012 vg/ml, respectively, for rAAV2/9-CMV-EGFP,
rAAV2/9-2YF-CMV-EGFP, and rAAV2/9-2YF-NF8-d1-EGFP.
ANIMALS
For the analysis of constitutive transgene expression from the
CMV promoter, adult female Wistar rats weighing approximately
200 g were used. For experiments with the KA model, adult male
Sprague–Dawley rats weighing approximately 200 g were used.
Animals were housed and treated according to the Belgian law.
The protocols were in accordance with national rules on animal
experiments and were approved by the Ethics Committee of the
Faculty of Medicine of the “Université Libre de Bruxelles.”
Animals were anesthetized with a mixture of ketamine (Imal-
gène 1000, Merial; 100 mg/kg) and xylazin (Rompun, Bayer;
10 mg/kg) and placed on a Kopf stereotaxic frame (Kopf Instru-
ments, Tujunga, CA, USA).
Intracisternal injections
The dura mater of the cisterna magna was made accessible by
incision of the neck skin and gentle separation of the subcutaneous
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tissue and muscles under anesthesia as previously described (Liu
andDuff, 2008). Tenminutes before virus injection a 25% solution
of D-mannitol (Sigma–Aldrich, M8429-100G) diluted in water
and sterilized by filtration was injected intraperitoneally (1 g/kg).
Next, 10 μl of viral suspension diluted at 1012 vg/ml was slowly
injected under microscope using a silicone-coated glass capillary
connected to a 50 μl Hamilton syringe via polyethylene tubing.
After viral infusion, the capillary wasmaintained in place for 2min
and then gently removed. The muscles were re-aligned, and the
skin was sutured.
Intraperitoneal KA injections
Five weeks after the virus injection, induction of status epilepti-
cus was performed as described earlier (Vermoesen et al., 2010).
Briefly, consecutive intraperitoneal KA injections (5 mg/kg,
diluted in PBS, Nanocs®) were administered at 30 min interval.
If a rat was nearing status epilepticus, half-doses (2.5 mg/kg) were
given in order to reduce mortality. Control rats were injected with
saline (NaCl 0.9%).
Perfusions
Animals were sacrificed one week after intraperitoneal KA injec-
tion and perfused intracardially first with saline, then with 4%
paraformaldehyde (PF4). Brains were post-fixed for 24 h in PF4.
IMMUNOHISTOCHEMISTRY
For GFP staining, vibratome coronal brain sections (50 μm)
were immunostained using anti-GFP antibodies using peroxidase
staining as previously described (Chtarto et al., 2013).
For CD11b staining, the procedure was the same except that
mouse monoclonal anti-CD11b (1:500, Serotec,MorphoSys, Dus-
seldorf, Germany) was used as a primary antibody and goat anti-
mouse IgG conjugated with HRP (Molecular Probes, Invitrogen,
Carlsbad, CA, USA, from TSA kit) as a secondary antibody.
Densitometric analysis of the staining was performed using the
image J software (NIH, USA).
QUANTIFICATION METHOD
Global brain transduction was quantified by two ways: cell density
and staining proportion.
Cell density was assessed by counting cells on microscope
pictures of known surface. All animals were photographed bilat-
erally on the same sections (same antero-posteriour level) at
the same location (dorsal or lateral) under the same condi-
tions (exposure, illumination) using an axioplan 2 microscope
(Zeiss) with a 10X/0,30 plan NEOFLUAR objective (Zeiss).
For cortex counting, 10 fields were photographed on five
sections encompassing the cortex from frontal cortex to the
beginning of the hippocampus. For hippocampus quantifica-
tion, eight fields on four sections were photographed and
counted.
Staining surface quantification was quantified on whole
section mosaic pictures. One section out of six of all injected
animals was DAB stained for GFP expression. All stained
sections were photographed using the mosaic function of
the Axiovision 4.8 software (Zeiss) on an imager M1 micro-
scope (Zeiss) equipped with a 10X/0,3 EC plan NEOFLUAR
objective (Zeiss). Section surface and stained surface were quan-
tified in pixel using the threshold function of ImageJ software
(NIH).
IMMUNOFLUORESCENCE
GFP labeling
Coronal brain sections (50 μm) obtained using a vibratome (Leica
Microsystems, Wetzlar, Germany) were incubated with a poly-
clonal rabbit anti-GFP (1:3000, Molecular Probes, Invitrogen,
Carlsbad, CA, USA) followed by a biotin-streptavidin-cyanine
2 fluorescent labeling as previously described (Bockstael et al.,
2012).
GFP: NeuN and GFP:GFAP co-labelings
For double immunofluorescence, the GFP labeling was combined
with mouse monoclonal antibodies [anti-NeuN or anti-glial fib-
rillary acid protein (GFAP)] followed by donkey anti-mouse IgG
coupled to cyanine 3 as previously described (Bockstael et al.,
2012).
GFP: IbaI co-labeling
For GFP:IbaI double immunofluorescence, the above described
GFP labeling was combined with goat anti-IbaI followed by a don-
key anti-goat A.568 antibody as previously described (Bockstael
et al., 2012).
GFP: Olig2 co-labeling
For GFP:Olig2 double immunofluorescence, a chicken mono-
clonal anti-GFP antibody and rabbit polyclonal anti-Olig2 IgG
were used as previously described (Bockstael et al., 2012).
In order to better visualize the structure of the tissue, cerebellar
sectionswere incubated in theHoescht 33258dye (Sigma–Aldrich)
diluted at 1 μg/ml in TBS for 30 min.
CONFOCAL MICROSCOPY
Co-labeling analysis was performed on pictures taken on at
least three different sections using a LSM510 NLO mul-
tiphoton confocal microscope fitted on an Axiovert M200
inverted microscope equipped with C-Apochromat 40×/1.2 N.A.
and 63×/1.2 N.A. water immersion objectives (Zeiss, Iena,
Germany).
The 488 nm excitation wavelength of the Argon/2 laser, a main
dichroicHFT 488 and a band-pass emission filter (BP500-550 nm)
were used for selective detection of the green fluorochrome (Cy2,
Alexa 488).
The 543 nm excitation wavelength of the HeNe1 laser, a main
dichroic HFT 488/543/633 and a long-pass emission filter (BP565-
615 nm) were used for selective detection of the red fluorochrome
(Cy3).
Optical sections, two microns thick, 512 × 512 pixels, were
collected sequentially for each fluorochrome. Z-stacks with a focus
step of one micron were collected.
The data-sets generated were merged and displayed with the
Zen software (Zeiss, 2009) and exported in LSM image format.
Counting was performed with the ImageJ 1.46a software (NIH,
USA). Figures were prepared with Adobe Photoshop CS3 soft-
ware.
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STATISTICAL ANALYSIS
All the statistical analysis was performed using the GraphPad
Software. Results were expressed as mean ± SD and statistical
significance was evaluated with student t-test (to compare pairs
of data sets). Differences were considered as significant when
p < 0.05.
RESULTS
GLOBAL BRAIN TRANSDUCTION AFTER INTRACISTERNAL DELIVERY OF
scAAV2/9 IS ENHANCED BY A RATIONALLY DESIGNED SURFACE
TYROSINE CAPSID MUTATION
It has been shown that gene delivery to the retina and the
brain of neonatal mice as well as newborn macaques through
FIGURE 1 | Locoregional brain transduction after intracisternal
delivery of scAAV2/9-2YF-CMV-EGFP. The scAAV2/9-2YF-CMV-EGFP
vector (1010 vg) was injected intracisternally. Five weeks after injection
the rats (n = 5) were perfused and brain sections of 50 μm were
labeled with anti GFP antibodies. The picture corresponds to an
antero-posterior succession of coronal rat brain sections. The mean
volume of transduction is 8.14% ± 3,3% of the whole brain. Scale bar:
5 mm.
FIGURE 2 | Brain transduction after intracisternal delivery of scAAV2/9
is enhanced by mutation of two surface tyrosines. Recombinant
scAAV2/9-CMV-EGFP and scAAV2/9-2YF-CMV-EGFP (1010 vg) were
injected intracisternally. Five weeks post-injection the rats were perfused
and vibratome brain sections of 50 μm were labeled with an anti GFP
antibody. The pictures show representatives examples of GFP-labeling in
the cortex (A,B) and of the hippocampus (D,E). Scale bar: 500 μm. The
cell density in the cortex (C) and in the hippocampus (F) was evaluated
as described in Section “Materials and Methods” and expressed as
number of cells per square millimeter (mm2). Data are expressed as
mean ± SD. The results obtained show more GFP-marked cells/mm2 of
section surface in scAAV2/9-2YF compared to scAAV2/9 injected rats both
in the cortex (C; p = 0,0395, student t -test) and in the hippocampus (F;
p = 0,0063, student t -test).
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FIGURE 3 | Cellular specificity of scAAV2/9-CMV-EGFP and
scAAV2/9-2YF-CMV-EGFP in the cortex. (A) Five weeks after injection
of scAAV2/9-CMV-EGFP (n = 5) or scAAV2/9-2YF-CMV-EGFP vector
(n = 5) into the cisterna magna, brain sections were double-labeled
with GFP (green fluorescence) and NeuN, GFAP or Olig2, (red
fluorescence). Confocal pictures show GFP and cell-specific markers in
double-labeled cells (yellow). GFP/NeuN, (a–c), GFP/GFAP, (d–f) and
GFP/Olig2, (g–i). Arrowheads indicate double-labeled cells. Scale bar:
40 μm. (B) the proportions of co-labeled cells were not significantly
different for the two vectors for NeuN (p = 0,3582, student t -test),
GFAP (p = 0,7971, student t -test)) and Olig2 (p = 0,7622, student
t -test). Open columns, scAAV2/9-CMV-EGFP; solid columns,
scAAV2/9-2YF-CMV-EGFP. Data are expressed as means ± SD. Analysis
was performed using confocal microscopy and counting the number
co-labeled cells on five sections per animal (n = 3 rats for GFP/NeuN,
GFP/GFAP and GFP/Olig2).
Frontiers in Molecular Neuroscience www.frontiersin.org December 2014 | Volume 7 | Article 92 | 5
Bockstael et al. Intracisternal delivery of pathology-inducible AAV
FIGURE 4 | Cellular specificity of scAAV2/9-CMV-EGFP and
scAAV2/9-2YF-CMV-EGFP in the hippocampus. (A) Five weeks after
injection of scAAV2/9-CMV-EGFP (n = 5) or scAAV2/9-2YF-CMV-EGFP
vector (n = 5) into the cisterna magna, brain sections were
double-labeled with GFP (green fluorescence) and NeuN, GFAP, or Olig2
(red fluorescence). Confocal pictures show GFP and cell-specific markers
in double-labeled cells (yellow). GFP/NeuN, (a–c), GFP/GFAP, (d–f) and
GFP/Olig2, (g–i). Arrowheads indicate double-labeled cells. Scale bar:
40 μm. (B) the proportions of co-labeled cells were not significantly
different for the two vectors for NeuN (p = 0,0602, student t -test) and
Olig2 (p = 0,0500, student t -test), but were significantly different for
GFAP (p = 0,0100, student t -test). Open columns, scAAV2/9-CMV-EGFP;
solid columns, scAAV2/9-2YF-CMV-EGFP. Data are expressed as
means ± SD. Analysis was performed using confocal microscopy and
counting the number co-labeled cells on five sections per animal (n = 3
rats for GFP/NeuN, GFP/GFAP, and GFP/Olig2).
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systemic intravenous injection of AAV2/9 was enhanced by
capsid tyrosine-to-phenylalanine mutant (Dalkara et al., 2012;
Dehay et al., 2012) in a site presumably involved in the ubiq-
uitination and the proteasomal degradation of AAV capsids
(Zhong et al., 2008). We injected titer-matched scAAV2/9-
CMV-EGFP and scAAV2/9-2YF-CMV-EGFP viral suspensions
(1012 vg/ml) in the cisterna magna of adult female Wis-
tar rats (scAAV2/9, n = 5; scAAV2/9-2YF, n = 5). One
month post-injection, animals were perfused and brains pro-
cessed for immunohistochemistry. Figure 1 shows the antero-
posterior distribution of GFP transgene expression in animals
injected with the scAAV2/9-2YF-CMV-EGFP vector. The label-
ing was present on all coronal sections from the anterior
cortex to the cerebellum. The right inset is a magnifica-
tion of the cerebellar area, showing the typical morpho-
logical organization of Purkinje neurons. Interestingly, the
density of GFP-positive cells was highest in the regions
bordered by the Virchow-Robin subarachnoid space (cortex
and cerebellum) and the third ventricle (hippocampus) in
which the CSF from the cisterna magna circulates. Figure 2
shows that the density of GFP-positive cells in the cortex
(Figures 2A–C) and in the hippocampus (Figures 2D–F) was
approximatively fivefold higher after scAAV2/9-2YF-CMV-EGFP
(Figures 2B,E) injection as compared to scAAV2/9-CMV-EGFP
(Figures 2A,D).
INTRACISTERNAL DELIVERY OF scAAV2/9 AND scAAV2/9-2YF USING
THE CONSTITUTIVE CMV PROMOTER MEDIATES GENE TRANSFER INTO
NEURONS, ASTROCYTES AND OLIGODENDROCYTES
With both vectors, the majority of cells expressing GFP were
neurons (labeled with NeuN marker; respectively, 42.9 ± 0.0%
and 49.9 ± 11.8% for scAAV2/9 and scAAV2/9-2YF, in the
FIGURE 5 | Kainic acid (KA)-induced microglial activation evidenced by
CD11b expression. Vibratome brain sections (50 μm) were immuno-labeled
using mouse anti-CD11b followed by streptavidin-biotin-peroxidase staining.
The intensity of the staining of four random areas within the cortex (A–C),
hippocampus (D–F), and the cerebellum (G–I), on every section was
quantified using the Image J program. Data are expressed as the mean
optical density ± SD (n = 4 for each group of animals). The difference
between KA and saline-treated groups was significant in the cortex
(p = 0,0118, student t -test), in the hippocampus (p = 0,0084, student t -test)
but not in the cerebellum (p = 0,5930, student t -test). Scale bar: 500 μm.
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cortex (Figure 3) and 73.7 ± 6% and 83.2 ± 1.8 in the
hippocampus (Figure 4). Astrocytes and oligodendrocytes were
also transduced with both vectors. Interestingly, the 2YF muta-
tion differentially affected the proportion of GFP-positive cells
expressing the GFAP astrocytic marker in the hippocampus
(25.6 ± 6.9% of the GFP-positive cells for scAAV2/9 ver-
sus 6.8 ± 1.5% for scAAV2/9-2YF; p = 0.01; Figure 4) but
not in the cortex (31.9 ± 9.4% of the GFP-positive cells for
scAAV2/9 versus 30.0 ± 6.9% for scAAV2/9-2YF; p = 0.7971;
Figure 3).
In contrast, the proportions of GFP-expressing cells whichwere
Olig2-positive oligodendrocytes were not significantly different
between both vectors, in both regions (Student t-test). However, a
tendency for a lower proportion of GFP:Olig2 double labeled cells
with the scAAV2/9-2YF mutant was observed in the hippocampus
(p = 0.050; student t-test).
No GFP-positive cells expressed the IbaI marker of microglial
cells with both vectors in both regions (data not shown).
INFLAMMATION-INDUCIBLE GENE DELIVERY RESPONSE TO SYSTEMIC
KA ADMINISTRATION IN THE CORTEX AND THE HIPPOCAMPUS
Injection of scAAV2/1-NF8-d1-EGFP into the hippocampal layers
followed, 1 month later by intraperitoneal KA injection resulted
in a strong transgene expression (Chtarto et al., 2013). However,
in order to determine which regions of the brain are affected by
the pathology, measured by NFκB activation, a global delivery of
the vector is desirable.
In the present study, we have therefore injected scAAV2/9-2YF-
NF8-d1-EGFP (1010 viral particles in 10 μl) in the cisterna magna
of adult rats. Two weeks later, intraperitoneal injections of KA
(n = 8) or saline as a control (n = 6) were performed. Ani-
mals were perfused 2 weeks post-treatment. KA induced a strong
FIGURE 6 | Kainic acid induces NFκB activation-dependent transgene
expression. Recombinant scAAV2/9-2YF-NF8-d1-EGFP (1010 vg) was
injected in the cisterna magna of Sprague–Dawley rats. The animals were
kept in two groups: one group was intraperitoneally injected with KA
(n = 8) 1 month post virus injection and the other group received only
saline (n = 6). The animals were sacrificed two weeks after injection.
Vibratome brain sections (50 μm) were immuno-labeled using anti-GFP
antibody. The pictures show representatives examples of GFP-labeling in
the cortex (A,B) and of the hippocampus (D,E). The cell density in the
cortex (C) and in the hippocampus (F) was evaluated as described in
Section “Materials and Methods.” Data are expressed as mean ± SD.
The results obtained in the cortex show a significant induction of GFP
expression in the KA-treated rats compared to saline treated rats
(p = 0,0207, student t -test). In the hippocampus the cell density in the
KA-treated rats is highly increased compared to the saline-treated rats
(p = 0,0005, student t -test). KA, kainic acid; saline, 0.9% NaCl. The cell
density per mm2 of section surface was correlated to the CD11B
intensity staining, respectively, in cortex (G; Correlation
Coefficient = 0,3353 and P = 0,1326) and hippocampus (H; Correlation
Coefficient = 0,8291 and p = 0,0017). Scale bar: 500 μm.
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inflammatory response characterized by prominent microglial
activation as evidenced by CD11b labeling in the hippocampus
and cortex but not in the cerebellum (Figure 5).
We then wanted to analyze whether the regional pattern of
GFP transgene expression driven by the NFκB-inducible pro-
moter corresponded to microglial activation. Indeed, Figure 6
shows representatives examples of GFP-labeling in the cortex
(Figures 6A,B) and of the hippocampus (Figures 6D,E). The
cell density in the cortex (Figure 6C) and in the hippocampus
(Figure 6F) was evaluated. The results obtained in the cortex
show a significant induction of GFP expression in the KA-treated
rats compared to saline treated rats (p = 0.0207, student t-test).
In the hippocampus the cell density in the KA-treated rats is
highly increased compared to the saline-treated rats (p = 0.0005,
student t-test). In contrast, in the untreated group, very few GFP-
positive cells were evidenced (see Figures 6A,D). The intensity
of the labeling in treated animals was variable both in terms
of surface area and number of cells labeled. This variability
could due to variability in the KA treatment efficacy (previously
reported) or to variability in the injections, also observed in the
AAVCMV group (see Figure 2). The cell density correlates to the
intensity of the CD11b staining in the hippocampus (H; Cor-
relation Coefficient = 0.8291 and p = 0.0017) but not in the
cortex (G; Correlation Coefficient = 0.3353 and P = 0.1326).
In addition, no GFP positive cell was evidenced in the cerebel-
lum after scAAV2/9-2YF-NF8-d1-EGFP in the cisterna magna
(Figure 7).
We then characterized the cellular specificity of scAAV2/9-2YF-
NF8-d1-EGFP-mediated transgene expression in KA-treated rats.
In both the hippocampus and the cortex, the vastmajority of GFP-
positive cells were neurons, with a very small percentage of labeled
astrocytes (Figure 8) and no oligodendrocyte or microglial cells
(data not shown)
DISCUSSION
Gene delivery to the whole brain has been described following
intravenous (Duque et al., 2009; Foust et al., 2009; Mccarty et al.,
2009; Fu et al., 2011; Gray et al., 2011) or intra- CSF rAAVadminis-
tration (Fu et al., 2003, 2010; Samaranch et al., 2012, 2013; Bucher
et al., 2013; Gray et al., 2013). Important differences exist in global
efficiency between different regions of the brain after intracisternal
vector injection, the superficial regions in the immediate vicinity
to the cranial sub-arachnoid space being more efficiently trans-
duced than the deeper regions (Samaranch et al., 2012). These
data suggest that penetration of the viral particles into deep brain
layers is limiting.
Here, we show that intracisternal injection of AAV2/9 leads
to gene transfer into neurons, astrocytes, and oligodendrocytes
with the highest efficiency in cortex, hippocampus, and cerebel-
lum and a lower efficiency in the striatum, and substantia nigra.
Additionally, we show that a rationally designed mutation replac-
ing two surface tyrosine supposedly involved in the recognition by
the ubiquitin-proteasome complex, by a phenylalanine residue
(Dalkara et al., 2012) enhanced global gene transfer efficiency.
Interestingly, the ratio of glial versus neuronal transgene expres-
sion was modified by the 2YF mutation in the hippocampus (but
not in the cortex), consistently with previous data obtained after
intravenous injection (Dalkara et al., 2012; see Supplementary
Figure 3).
Finally, we demonstrate that in response to systemic KA
administration, transgene expression from a NFκB-responsive
promoter was induced in the hippocampus and the cortex but
not in the cerebellum. Our data are consistent with a previ-
ously published study showing that the expression of NFκB was
increased in the cortex and slightly decreased in the cerebellum
following intraperitoneal injections of KA (Rong and Baudry,
1996).
The CSF produced in the choroid plexus is thought to travel
to the cisterna magna, then in the Virchow-Robin subarachnoid
space and flow into brain parenchyma along cerebral arteries.
Molecules dissolved in the CSF are exchanged between perivas-
cular spaces and brain interstitial fluids from which they can
penetrate the brain parenchyma through the spaces between astro-
cytic feet and the basal laminae. These exchanges were suggested
to require aquaporin-4 (Iliff et al., 2012; see Figure 9). The brain
penetration properties of molecules administered into the cisterna
magna varies with the size of the molecules. Small dyes enter the
brain by diffusion into the interstitial fluid through gaps between
astrocytic feet and the capillaries basal laminae whereas large
molecules (2000 kD) similar to AAV particles (MW of approx-
imately 4000 KD) remain confined in the perivascular spaces.
They do not enter the interstitial fluid (Iliff et al., 2012). From
the cisterna magna, viral particles are thus expected to circulate in
FIGURE 7 | Kainic acid does not induce NFκB activation-mediated
transgene expression in the cerebellum. KA (5 mg/kg) was injected
intraperitoneally 5 weeks after intracisternal injection of
scAAV2/9-2YF-NF8-d1-EGFP. Fifty μm coronal sections were labeled with
GFP antibodies. Scale bar: 500 μm.The GFP staining is almost inexistent in
KA- and saline-treated rats injected with scAAV2/9-2YF-NF8-d1-EGFP (A,B)
while a strong GFP staining was demonstrated in rats injected with
scAAV2/9-2YF-CMV-EGFP (C).
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FIGURE 8 | Cellular specificity of NFκB activation-mediated transgene
expression. KA (5 mg/kg) was injected intraperitoneally 1 month after
intracisternal injection of scAAV2/9-2YF-NF8-d1-EGFP. Fifty μm coronal
sections were double-labeled with GFP (green fluorescence) and NeuN
(GFP/NeuN, a–c in the cortex and g–i in the hippocampus) or GFAP
(GFP/GFAP, d–f in the cortex and j–l in the hippocampus). Confocal
pictures show GFP and cell-specific markers double-labeled cells (yellow;
A). Arrowheads indicate double-labeled cells. Scale bar: 40 μm. The mean
percentage of GFP-positive cells co-labeling with the GFAP and NeuN
markers are shown (B). Open columns, cortex; solid columns,
hippocampus. Data are expressed as means ± SD. Analysis was
performed using confocal microscopy and counting the number of
co-labeled cells on five sections per animal (n = 3 rats for GFP/NeuN and
GFP/GFAP, n = 3).
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the Virchow-Robin subarachnoid space and enter the brain along
spaces aroundpenetrating blood vessels. Themechanismbywhich
AAV particles, enter the brain interstitial fluid is unknown. The
fact that AAV2 particles transduce the brain after intracisternal
delivery (Fu et al., 2003) exclusively in the presence of mannitol,
suggests that the up-regulation of expression of aquaporin 4 by
mannitol (Mccarty et al., 2009; Fu et al., 2010) may play a role of
the entry of particles (Arima et al., 2003). In contrast, cisternally
injected AAV2/9 particles enter the brain regardless of the pres-
ence of mannitol or sorbitol. However, the use of sorbitol (Gray
et al., 2011) or mannitol (Bockstael et al., unpublished observa-
tions) enhanced transduction efficiency. Mannitol also enhanced
trans-brain–blood barrier gene delivery mediated by AAV2/9 (Fu
et al., 2011). Altogether these data suggest that the mechanism of
viral particles entry into the brain parenchyma after intravascu-
lar and intra-CSF administration might share at least a common
pathway involving the aquaporin 4 water channel.
Compared to intravenous injections, injections into the CSF
were shown to reduce the bio-distribution of vectors into periph-
eral organs (Gray et al., 2013) as well as avoiding the inhibitory
effect on gene transfermediatedby anti-AAVneutralizing antibod-
ies (Gray et al., 2013). However, a strong inflammatory response
to non-self-transgene products and elimination of transduction
was observed in primates (Samaranch et al., 2014). This can be
explained by the presence of activated T secreting cytokines at the
choroid plexus-brain interface which can in some circumstances
enter the CNS (Schwartz and Baruch, 2014).
We have previously established a proof-of-concept for disease-
inducible gene delivery in the brain using an AAV vector respond-
ing to NFκB activation as a probe for inflammatory responses
(Chtarto et al., 2013). In this study, the reporter vector was injected
focally in the parenchyma prior to a systemic KA injection and
mediated inducible and specific transgene expression in the hip-
pocampus but not in the cerebellum, regions, respectively, known
to be affected or spared by the pathology (Rong andBaudry, 1996).
However, such a focal approach relies on the knowledge of the
mechanism of disease induction/progression in the animal model.
Vector delivery in the CSF allows to reveal the pathology as well
as to deliver therapeutic factors in several affected brain regions
after a single vector injection and in a disease-regulated manner.
However, in order to reflect the regional specificity of the disease,
the distribution of the transgene product should be homogenous
throughout the brain. In our study, the distribution of transgene
expression is heterogeneous,with ahigher efficiency in cerebellum,
cortex, andhippocampus and a limited efficiency in deeper regions
such as striatum. Methods to stimulate the perivascular pump or
increase the functionality of water channels at the astrocytic feet
could enhance viral particle penetration into the brain.
In other recent studies, the model of CSF circulation has been
challenged and it has proposed that CSF is reabsorbed into brain
capillaries (Pardridge, 2011). Thus AAV2/9 viral particles might
first enter the brain capillaries than subsequently enter into the
brain parenchyma through the blood-brain-barrier.
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